ClinicalTrials.gg

Program

daromun

Also written as “L19IL2/L19TNF” and “Daromun”.

Its studies are mostly in Carcinoma, Basal Cell · Melanoma, led by Philogen.

Furthest: phase 3, since May 18, 20186 company-led studies, 6 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Philogen66 open or runningphase 3since May 18, 2018May 18, 2018Dec 2027phase 3 · NCT03567889

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2018First study: phase 3 study in MelanomaFirst studyNCT03567889 · 186 planned · United States, Spain, Switzerland
  2. Apr 7, 2022Phase 2 study in Carcinoma, Basal CellNCT05329792 · 70 planned · France, Italy, Spain
  3. Jan 26, 2024Phase 2 study in MelanomaNCT06284590 · 162 planned · United States, Germany, Italy
  4. Nov 7, 20253 phase 2 studiesNCT07228442, NCT07227870, NCT07227350

Ahead

  1. Dec 2027Primary completion: phase 3 study in MelanomaNCT03567889
  2. Jul 2028Primary completion: phase 2 study in MelanomaNCT06284590
  3. Feb 2031Primary completion: phase 2 study in Locally Advanced Cutaneous Squamous Cell CarcinomaNCT07228442
  4. Feb 2031Primary completion: phase 2 study in Carcinoma, Basal CellNCT07227870

TargetBeta

IL2 →read by rule
“A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), ”NCIt, by rule

Other programs on IL2

ProgramCompanyFurthest phaseStudies
darleukinrulePhilogenphase 39
Daxokafusp AlfaSanofiphase 22
SAR444336Sanofiphase 22
Anti-PD-1/IL-2 Fusion Protein TEV-56278Teva Pharmaceutical Industriesphase 12
IL-2 Mutein/Fc Fusion Protein HM16390ruleHanmi Pharmaceuticalphase 11
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101ruleoutpace-bio-incphase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma · United States, Germany, Greece and more2RecruitingFeb 203192
NCT07227870Carcinoma, Basal Cell · United States, Germany, Greece and more2RecruitingFeb 203192
NCT07227350Carcinoma, Basal Cell · United States, Germany, Greece and more2RecruitingFeb 2031180
NCT06284590Melanoma · United States, Germany, Italy2RecruitingJul 2028162
NCT05329792Carcinoma, Basal Cell · France, Italy, Spain2RecruitingJun 202470
NCT03567889Melanoma · United States, Spain, Switzerland3RecruitingDec 2027186

How it is read

Names in the registry

  • “L19IL2/L19TNF”, 5 entries
  • “Daromun”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.